A significant proportion of breast cancer cells with mutations in PTEN or Class 1 PI3K are inherently resistant to inhibitors of PI3K or Akt, as they express high levels of SGK1 that can substitute for Akt [27,28]. This evidence concerns the gene AKT1 and breast cancer.